{"schema_version":"secwatch.filing_event.v1","accession":"0001006837-26-000013","form_type":"8-K","ticker":"VATE","cik":"0001006837","company_name":"INNOVATE Corp.","filed_at":"2026-03-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.389952+00:00","generated_at":"2026-05-15T08:46:40.559266+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"INNOVATE Q4 rev surges 62% to $382.7M; net loss narrows to $7.8M; backlog $1.8B","bullets":["Q4 revenue $382.7M (+61.7% YoY); net loss $7.8M ($0.58 EPS) vs $16.9M loss a year ago.","FY 2025 revenue $1.246B (+12.5%); net loss $64.0M ($4.84 EPS) vs $35.8M loss in 2024.","Q4 total Adjusted EBITDA $24.5M (+63.3% YoY); FY Adj EBITDA $67.2M, down 5.8% from $71.3M.","DBMG (Infrastructure) backlog $1.8B, up from $1.1B a year ago; Q4 segment revenue $373.9M (+65.7%).","R2 Life Sciences secured 600-system minimum purchase commitment in China; MediBeacon got FDA approval for next-gen TGFR."],"urls":{"canonical":"https://secwatch.observer/filing/0001006837-26-000013","json":"https://secwatch.observer/filing/0001006837-26-000013.json","markdown":"https://secwatch.observer/filing/0001006837-26-000013.md","text":"https://secwatch.observer/filing/0001006837-26-000013.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1006837/000100683726000013/0001006837-26-000013-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1006837/000100683726000013/vate-20260326.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:46:40.559266+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9482e8c73b963bc0add08280a7b585c816b7d77f","claim":"INNOVATE Corp. reported the fourth quarter and full year ended December 31, 2025 results: revenue $ 382.7, net income $ (7.8), EPS $(0.58).","evidence_excerpt":"Summary (in millions, except per share amounts) Three Months Ended December 31, Year Ended December 31, 2025 2024 Increase / (Decrease) 2025 2024 Increase / (Decrease) Revenue $ 382.7 $ 236.6 61.7 % $ 1,246.0 $ 1,107.1 12.5 % Net loss attributable to common stockholders and participating preferred stockholders $ (7.8) $ (16.9) 53.8 % $ (64.0) $ (35.8) (78.8) %","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1006837/000100683726000013/0001006837-26-000013-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2025"},{"label":"Revenue","value":"$ 382.7"},{"label":"Net income","value":"$ (7.8)"},{"label":"EPS","value":"$(0.58)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}